Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced... Key PointsQuestionIs pembrolizumab monotherapy safe and effective in patients with previously treated gastric and gastroesophageal junction cancer? FindingsAmong 259 patients with previously treated gastric and gastroesophageal junction cancer enrolled in the phase 2 KEYNOTE-059 single-arm, multicohort trial, pembrolizumab demonstrated manageable safety. The objective response rate was 11.6% (30 of 259 patients), and complete responses were observed in 2.3% of patients (6 of 259); the median (range) response duration was 8.4 (1.6 + to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). MeaningThese results support further development of pembrolizumab for patients with gastric and gastroesophageal junction cancer who have received 2 or more lines of therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/safety-and-efficacy-of-pembrolizumab-monotherapy-in-patients-with-oquAaCACA2

References (43)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.0013
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionIs pembrolizumab monotherapy safe and effective in patients with previously treated gastric and gastroesophageal junction cancer? FindingsAmong 259 patients with previously treated gastric and gastroesophageal junction cancer enrolled in the phase 2 KEYNOTE-059 single-arm, multicohort trial, pembrolizumab demonstrated manageable safety. The objective response rate was 11.6% (30 of 259 patients), and complete responses were observed in 2.3% of patients (6 of 259); the median (range) response duration was 8.4 (1.6 + to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). MeaningThese results support further development of pembrolizumab for patients with gastric and gastroesophageal junction cancer who have received 2 or more lines of therapy.

Journal

JAMA OncologyAmerican Medical Association

Published: May 15, 2018

There are no references for this article.